Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5601_Библиотеки_им_академика_М_И_Перельмана

One of the new developments in the treatment of diabetes is the possibility of leptin therapy. It is an adipocyte-secreted hormone that works on neurons within the central nervous system. The various acts of this hormone include regulating excessive weight gain by suppressing food consumption and increasing energy expenditure. By activating leptin receptors (LEPRs), leptins also control glucose homeostasis. The central nervous system has been shown to control the sugar­lowering activity of leptins; it was thought that neurons in the brain concerning type 1 diabetes may have affected the antidiabetic function of leptins. Leptin therapy through CNS-dependent pathways in mice enhances insulin-deficient type 1 diabetes. Another field of drug study concerns the creation and use of multi­drug mucoadhesive microcapsules such as glipizide to ensure the controlled release and successful targeting of the drug. Mucoadhesion has become a novel method in the design of drug delivery because it triggers the gradual release of the drug at the site of action or absorption, thereby increasing the drug's contact with the underlying tissue, thus, improving the drug's bioavailability. The drug delivery methods that have been followed as a potential solution for diabetes have no end. The approach to transdermal insulin administration (developed because of unpleasant and complex insulin therapy) retains excessive amounts of insulin without insulin deposits in the skin, often with subcutaneous injections of insulin.